Klotho Neurosciences, Inc. (NASDAQ:Â KLTO) is a biogenetics company focused on the development of innovative, disease-modifying cell and gene therapies using a protein derived from a patented form of the "anti- aging" human Klotho gene (s-KL), and its novel delivery systems to transform and improve the treatment of neurodegenerative and age-related disorders such as ALS, Alzheimer's disease, and Parkinson's disease. The Company's current portfolio consists of its proprietary cell and gene therapy programs u ...

Biogenetics company Klotho Neurosciences has announced plans to acquire assets from Turn Biotechnologies, marking a move in the development of longevity therapeutics. Turn Biotechnologies is focused on induced pluripotent stem cells (iPSCs) and cellular reprogramming. Klotho has signed a letter of intent (LOI) in this regard. The cash and stock deal is contingent upon the completion of due diligence, the execution of a definitive agreement and fulfilment of typical closing conditions. Under the LOI's t ...

Accessibility StatementSkip Navigation NEW YORK and PALO ALTO, Calif., Sept. 30, 2025 /PRNewswire/ --Â Klotho Neurosciences, Inc. (Nasdaq: KLTO, "Klotho" or "the Company") today announced it has signed a Letter of Intent (LOI) to acquire select assets from Turn Biotechnologies, Inc. ("Turn"), a leader in induced pluripotent stem cells (iPSC) and cellular reprogramming. The proposed cash and stock transaction is subject to completion of due diligence, execution of a definitive agreement, and customary closin ...